Premium
Primary cutaneous acral CD 8 + T‐cell lymphomas relapse more frequently in younger patients
Author(s) -
Maubec Eve,
Marinho Eduardo,
Laroche Liliane,
Mitchell Andrew,
Grange Florent,
Petrella Tony
Publication year - 2019
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.15572
Subject(s) - immunophenotyping , medicine , cd8 , gene rearrangement , cd5 , pathology , cd30 , lymphoma , t cell , immunology , biology , antigen , immune system , biochemistry , gene
noma. Oncologist, 21, 1218–1229. Martinelli, G., Oehler, V.G., Papayannidis, C., Courtney, R., Shaik, M.N., Zhang, X., O’Connell, A., McLachlan, K.R., Zheng, X., Radich, J., Baccarani, M., Kantarjian, H.M., Levin, W.J., Cortes, J.E. & Jamieson, C. (2015) Treatment with PF-04449913, an oral smoothened antagonist, in patients with myeloid malignancies: a phase 1 safety and pharmacokinetics study. Lancet Haematology, 2, e339– e346. O’Donnell, M.R., Tallman, M.S., Abboud, C.N., Altman, J.K., Appelbaum, F.R., Arber, D.A., Bhatt, V., Bixby, D., Blum, W., Coutre, S.E., De Lima, M., Fathi, A.T., Fiorella, M., Foran, J.M., Gore, S.D., Hall, A.C., Kropf, P., Lancet, J., Maness, L.J., Marcucci, G., Martin, M.G., Moore, J.O., Olin, R., Peker, D., Pollyea, D.A., Pratz, K., Ravandi, F., Shami, P.J., Stone, R.M., Strickland, S.A., Wang, E.S., Wieduwilt, M., Gregory, K. & Ogba, N. (2017) Acute myeloid leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 15, 926–957. Pollyea, D.A., Gutman, J.A., Gore, L., Smith, C.A. & Jordan, C.T. (2014) Targeting acute myeloid leukemia stem cells: a review and principles for the development of clinical trials. Haematologica, 99, 1277–1284. Sekulic, A., Migden, M.R., Oro, A.E., Dirix, L., Lewis, K.D., Hainsworth, J.D., Solomon, J.A., Yoo, S., Arron, S.T., Friedlander, P.A., Marmur, E., Rudin, C.M., Chang, A.L., Low, J.A., Mackey, H.M., Yauch, R.L., Graham, R.A., Reddy, J.C. & Hauschild, A. (2012) Efficacy and safety of vismodegib in advanced basal-cell carcinoma. New England Journal of Medicine, 366, 2171–2179. Tibes, R., Kosiorek, H.E., Dueck, A.C., Sproat, L., Palmer, J., Slack, J.L., Singh, D., Gebhart, E., Knight, E., Hashmi, S.K., Wilcox, R.A., Bogenberger, J.M., Mesa, R.A. & Al-Kali, A. (2015) Phase I/IB study of azacitidine and hedgehog pathway inhibition in myeloid malignancies. Blood, 126, 1347. Visser, O., Trama, A., Maynadie, M., Stiller, C., Marcos-Gragera, R., De Angelis, R., Mallone, S., Tereanu, C., Allemani, C., Ricardi, U., Schouten, H.C. & Group, R.W. (2012) Incidence, survival and prevalence of myeloid malignancies in Europe. European Journal of Cancer, 48, 3257–3266. Wellbrock, J., Latuske, E., Kohler, J., Wagner, K., Stamm, H., Vettorazzi, E., Vohwinkel, G., Klokow, M., Uibeleisen, R., Ehm, P., Riecken, K., Loges, S., Thol, F., Schubert, C., Amling, M., Jucker, M., Bokemeyer, C., Heuser, M., Krauter, J. & Fiedler, W. (2015) Expression of Hedgehog pathway mediator GLI represents a negative prognostic marker in human acute myeloid leukemia and its inhibition exerts antileukemic effects. Clinical Cancer Research, 21, 2388–2398.